Highlights Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.17 ^USD	-10.00%		-3.31%	-63.89%

Apr. 22	Sector Update: Health Care Stocks Increase Late Afternoon	MT
Apr. 22	Sector Update: Health Care	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	Apr. 22	DJ
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	Apr. 19	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	Nov. 13	CI
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	23-10-25	CI
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat	23-09-21	CI
Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study	23-09-14	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat	23-06-15	CI
Hepion's NASH drug meets main goal in mid-stage trial	23-05-22	RE
Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial	23-05-22	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-10	CI
Hepion Pharmaceuticals Secures European Patent for Liver Disease Drug Candidate Rencofilstat	23-03-02	MT
Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma	23-01-18	CI
Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors	23-01-10	CI
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial	22-12-05	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results	22-10-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Highlights

Filters